These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 28689093)
1. Immune checkpoint inhibitors and elderly people: A review. Daste A; Domblides C; Gross-Goupil M; Chakiba C; Quivy A; Cochin V; de Mones E; Larmonier N; Soubeyran P; Ravaud A Eur J Cancer; 2017 Sep; 82():155-166. PubMed ID: 28689093 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy and elderly people: A review. Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351 [TBL] [Abstract][Full Text] [Related]
3. [Development of immune checkpoint inhibitors]. Kitano S Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282 [TBL] [Abstract][Full Text] [Related]
4. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts? Jackaman C; Nelson DJ Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067 [TBL] [Abstract][Full Text] [Related]
6. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Koster BD; de Gruijl TD; van den Eertwegh AJ Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539 [TBL] [Abstract][Full Text] [Related]
7. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Matlung HL; Szilagyi K; Barclay NA; van den Berg TK Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703 [TBL] [Abstract][Full Text] [Related]